Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union
Advertisement

Related Content

Mexico And Brazil Release Biosimilars Guidelines, But Not All Issues Resolved
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
Biosimilars Tidal Wave May Well Create A $10 Bill. Opportunity By 2015 For Indian Companies
3SBio Files For Approval For Interleukin-2 NuLeusin
3SBio Files For Approval For Interleukin-2 NuLeusin
Advertisement
UsernamePublicRestriction

Register

SC072611

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel